A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Pharmacodynamics of Increasing Subcutaneous Doses of SEL-068 in Healthy Non-Smoker and Smoker Adults
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2016
At a glance
- Drugs SEL 068 (Primary)
- Indications Smoking withdrawal
- Focus Adverse reactions
- Sponsors Selecta Biosciences
- 06 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Dec 2012 Planned end date changed from 1 Oct 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov record.
- 05 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.